サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1617124

内視鏡的逆行性胆管膵管造影装置市場の2030年までの予測：製品タイプ、技術、用途、エンドユーザー、地域別の世界分析

Endoscopic Retrograde Cholangiopancreatography Devices Market Forecasts to 2030 - Global Analysis by Product, Type, Technology, Application, End User and By Geography

出版日
ページ情報
英文 200+ Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
内視鏡的逆行性胆管膵管造影装置市場の2030年までの予測：製品タイプ、技術、用途、エンドユーザー、地域別の世界分析
出版日: 2024年12月11日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、世界の内視鏡的逆行性胆管膵管造影（ERCP）装置市場は、2024年に16億2,860万米ドルを占め、予測期間中にCAGR 8.3％で成長し、2030年には26億2,770万米ドルに達すると予測されています。

内視鏡的逆行性胆管膵管造影（ERCP）装置は、胆道や膵管の診断や治療に使用される専門医療機器です。ERCPでは内視鏡検査と透視検査が組み合わされ、悪性腫瘍、狭窄、胆管結石を観察・治療します。手術では、口から十二指腸に軟性内視鏡を挿入します。そこで、生検鉗子、拡張器、ステント、カテーテルなどの専用器具を使用して、閉塞を除去したり、ステントを留置したり、組織サンプルを採取したりします。高精度で低侵襲なソリューションを提供するため、ERCP装置は膵臓および胆道疾患の診断と治療に不可欠です。

National Cancer Databaseによると、米国における膵がん診断の68.5%は65歳以上で行われています。

胆道および膵疾患の有病率の増加

胆石、胆管狭窄、膵炎などの胆道・膵臓疾患の有病率の増加は、内視鏡的逆行性胆管膵管造影（ERCP）装置の需要を押し上げています。これらの疾患の効果的な治療は、正確な診断と治療にかかっており、ERCP手技は極めて重要です。特に高齢者における症例数の増加がERCP機器の使用を促し、市場拡大を後押ししています。ERCPの低侵襲治療と早期発見が患者の転帰を向上させるため、市場はさらに拡大しています。

ERCP手技と装置の高コスト

ERCPの手技や機器のコストが高いことが、特にヘルスケア資源が限られている中低所得国での市場拡大を妨げています。専門医の必要性、高額な機器費用、手技費用などが、病院や診療所がERCP技術を導入する意欲を削ぐ可能性があります。さらに、治療上の利点があるにもかかわらずERCP装置の幅広い普及を妨げているのは、保険適用と支払いの問題であり、こうした最先端の手技への患者のアクセスを制限する可能性があります。

低侵襲手技の進歩

低侵襲手技の進歩は、治療の精度と安全性を向上させることで、ERCP機器市場に大きな影響を与えています。改善された内視鏡画像、よりコンパクトで柔軟な装置、洗練された生検器具は、患者の回復期間を短縮しながらより良い治療結果と診断を可能にする技術革新の一例です。患者が標準的な手術に代わる、より侵襲の少ない方法を選択するにつれて、ERCP装置の需要はますます高まっています。こうした開発は、治療の選択肢を増やし、問題を減らし、手技を合理化することでもあり、市場の成長を支えています。

合併症のリスク

膵炎、出血、感染症などの合併症のリスクがERCP装置の普及を妨げています。特にリスクの高い状況では、こうした危険性があるため、患者がERCPを選択する意欲を失い、医療従事者もERCPを支持しなくなる可能性があります。さらに、すべての施設がこのような高度な手技を安全に実施できるわけではないため、困難を軽減するために高度な資格を有する専門家が必要となり、コストが上昇し、市場拡大の妨げとなる可能性があります。

COVID-19の影響：

COVID-19の流行は内視鏡的逆行性胆管膵管造影（ERCP）機器市場に大きな影響を与え、ヘルスケアシステムの緊張による選択的処置の遅延やキャンセルにつながった。その結果、ERCP機器の需要が減少しました。しかし、ヘルスケアシステムの回復に伴い、特に消化管・胆道疾患に対する低侵襲診断・治療手技への注目が高まり、市場は回復すると予想されます。

予測期間中、生検鉗子分野が最大となる見込み

膵・胆道疾患に対する正確な診断技術へのニーズが高まっていることから、生検鉗子分野は予測期間中に最大となる見込み。ERCPの際、生検鉗子は組織サンプルの採取を可能にし、狭窄、がん、その他の異常の早期診断に役立ちます。生検鉗子の使用は、消化器疾患の増加や低侵襲手技の向上により増加しています。安全性と精度の向上は、市場拡大を支えるもう2つの設計要素です。

予測期間中にCAGRが最も高くなると予想されるのはダイレーター分野

胆道系疾患の有病率の上昇、低侵襲手術手技の進歩、正確で効果的な手技への要望の高まりにより、ダイレーター分野の予測期間中のCAGRは最も高くなると予想されます。内視鏡のスムーズな通過を確保するためには、膵管や胆管の狭窄を拡張するためのダイレーターが必要です。ERCP機器市場は、ダイレーターの使用を促す使い捨て、人間工学に基づいたデザイン、強化された安全機能などの技術的進歩の結果として拡大しています。

最大のシェアを占める地域

膵炎、胆管がん、胆石などの胆道疾患が一般化していることから、予測期間中は北米が最大の市場シェアを占めると予想されます。ERCP装置の技術開発により、画像システムの強化や低侵襲治療など、治療精度や患者の転帰が改善されています。さらに、同地域の高いヘルスケア支出、確立されたヘルスケア・インフラ、最先端医療技術の利用増加などが、ERCP機器の需要増加を支えており、市場の拡大を後押ししています。

CAGRが最も高い地域：

アジア太平洋地域は、ヘルスケアインフラの増加、胆道および膵臓疾患の発生率の上昇、高齢化人口の増加により、予測期間中に最も高いCAGRを記録すると予測されています。画像診断や低侵襲技術の向上など、ERCP技術の進歩が診断・治療能力を高めています。さらに、この地域のヘルスケアアクセスの拡大、医療ツーリズムの増加、先進医療機器の採用がERCP機器の需要を押し上げ、アジア太平洋地域の市場成長に拍車をかけています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

  • 企業プロファイル
    • 追加市場企業の包括的プロファイリング（3社まで）
    • 主要企業のSWOT分析（3社まで）
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データマイニング
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査情報源
    • 1次調査情報源
    • 2次調査情報源
    • 前提条件

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 機会
  • 脅威
  • 製品分析
  • 技術分析
  • 用途分析
  • エンドユーザー分析
  • 新興市場
  • COVID-19の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界の内視鏡的逆行性胆道膵管造影（ERCP）装置市場：製品別

  • 内視鏡治療装置
  • 内視鏡
  • イメージングデバイス
  • 括約筋切開術
  • ステント
  • バルーンカテーテル
  • 生検鉗子
  • ガイドワイヤー
  • 拡張器
  • その他の製品

第6章 世界の内視鏡的逆行性胆道膵管造影（ERCP）装置市場：タイプ別

  • 従来のERCP
  • シングルオペレーターERCP
  • 腹腔鏡下ERCP
  • 超音波内視鏡（EUS）ガイド下ERCP
  • その他のタイプ

第7章 世界の内視鏡的逆行性胆道膵管造影（ERCP）装置市場：技術別

  • 高度な画像システム
  • ロボット支援ERCP
  • AIと機械学習との統合
  • その他の技術

第8章 世界の内視鏡的逆行性胆道膵管造影（ERCP）装置市場：用途別

  • 診断用ERCP
    • 胆管がん
    • 膵炎
    • 胆石
    • 胆道狭窄
  • 治療的ERCP
    • 石の抽出
    • ステント留置
    • 括約筋切開術
    • 狭窄部の拡張
    • 感染した胆汁の排出
  • その他の用途

第9章 世界の内視鏡的逆行性胆道膵管造影（ERCP）装置市場：エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター
  • 研究・学術機関
  • その他のエンドユーザー

第10章 世界の内視鏡的逆行性胆道膵管造影（ERCP）装置市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東・アフリカ

第11章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品発売
  • 事業拡大
  • その他の主要戦略

第12章 企業プロファイリング

  • AMBU, Inc.
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Group
  • FUJIFILM Holdings Corporation
  • Hobbs Medical, Inc.
  • HOYA Group
  • Karl Storz SE & Co. KG
  • Medi-Globe GmbH
  • Medline Industries, Inc.
  • Medtronic PLC
  • Olympus Corporation
  • Streis PLC
  • Stryker Corporation
  • Taewoong Medical Co., Ltd.
  • Telemed System, Inc.
図表

List of Tables

  • Table 1 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Endotherapy Devices (2022-2030) ($MN)
  • Table 4 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Endoscopes (2022-2030) ($MN)
  • Table 5 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Imaging Devices (2022-2030) ($MN)
  • Table 6 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Sphincterotomes (2022-2030) ($MN)
  • Table 7 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Stents (2022-2030) ($MN)
  • Table 8 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Balloon Catheters (2022-2030) ($MN)
  • Table 9 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Biopsy Forceps (2022-2030) ($MN)
  • Table 10 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Guidewires (2022-2030) ($MN)
  • Table 11 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Dilators (2022-2030) ($MN)
  • Table 12 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 13 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Type (2022-2030) ($MN)
  • Table 14 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Conventional ERCP (2022-2030) ($MN)
  • Table 15 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Single-Operator ERCP (2022-2030) ($MN)
  • Table 16 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Laparoscopic ERCP (2022-2030) ($MN)
  • Table 17 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Endoscopic Ultrasound (EUS)-Guided ERCP (2022-2030) ($MN)
  • Table 18 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 19 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Technology (2022-2030) ($MN)
  • Table 20 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Advanced Imaging Systems (2022-2030) ($MN)
  • Table 21 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Robotic-Assisted ERCP (2022-2030) ($MN)
  • Table 22 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Integration with AI and Machine Learning (2022-2030) ($MN)
  • Table 23 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 24 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Application (2022-2030) ($MN)
  • Table 25 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Diagnostic ERCP (2022-2030) ($MN)
  • Table 26 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Cholangiocarcinoma (2022-2030) ($MN)
  • Table 27 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Pancreatitis (2022-2030) ($MN)
  • Table 28 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Gallstones (2022-2030) ($MN)
  • Table 29 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Biliary Strictures (2022-2030) ($MN)
  • Table 30 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Therapeutic ERCP (2022-2030) ($MN)
  • Table 31 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Stone Extraction (2022-2030) ($MN)
  • Table 32 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Stent Placement (2022-2030) ($MN)
  • Table 33 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Sphincterotomy (2022-2030) ($MN)
  • Table 34 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Dilation of Strictures (2022-2030) ($MN)
  • Table 35 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Drainage of Infected Bile (2022-2030) ($MN)
  • Table 36 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 37 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By End User (2022-2030) ($MN)
  • Table 38 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 39 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 40 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
  • Table 41 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Research and Academic Institutions (2022-2030) ($MN)
  • Table 42 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次
Product Code: SMRC28002

According to Stratistics MRC, the Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market is accounted for $1628.6 million in 2024 and is expected to reach $2627.7 million by 2030 growing at a CAGR of 8.3% during the forecast period. Endoscopic Retrograde Cholangiopancreatography (ERCP) devices are specialist medical equipment used to perform diagnostic and therapeutic treatments on the bile and pancreatic channels. Endoscopy and fluoroscopy are combined in ERCP to view and treat malignancies, strictures, and bile duct stones. A flexible endoscope is inserted through the mouth into the duodenum during the surgery. There, specialized tools such as biopsy forceps, dilators, stents, and catheters are used to clear blockages, put stents, or take tissue samples. Because they provide highly accurate, minimally invasive solutions, ERCP devices are essential for the diagnosis and treatment of pancreatic and biliary disorders.

According to the National Cancer Database, 68.5% of pancreatic cancer diagnoses in the United States are made in people over 65 years old.

Market Dynamics:

Driver:

Increasing Prevalence of Biliary and Pancreatic Disorders

The growing prevalence of biliary and pancreatic illnesses, such as gallstones, bile duct strictures, and pancreatitis, pushes up demand for Endoscopic Retrograde Cholangiopancreatography (ERCP) equipment. Effective management of these disorders depends on precise diagnosis and treatment, which makes ERCP procedures crucial. The growing number of instances, especially in older populations, encourages the use of ERCP devices and propels market expansion. The market is further expanded by ERCP's minimally invasive treatments and early identification, which enhance patient outcomes.

Restraint:

High Cost of ERCP Procedures and Devices

The high cost of ERCP procedures and equipment stifles market expansion, especially in low- and middle-income countries with restricted healthcare resources. The necessity for specialist personnel, high equipment costs, and procedural expenses may discourage hospitals and clinics from implementing ERCP technology. Further impeding the broad adoption of ERCP devices despite their therapeutic benefits are insurance coverage and payment issues, which can limit patient access to these cutting-edge procedures.

Opportunity:

Advancements in Minimally Invasive Procedures

Advances in minimally invasive techniques have a substantial impact on the ERCP device market by improving treatment precision and safety. Improved endoscopic imaging, more compact and flexible devices, and sophisticated biopsy instruments are examples of innovations that allow for better therapy results and diagnostics while shortening recuperation periods for patients. ERCP devices are becoming more and more in demand as patients choose less intrusive alternatives to standard surgery. These developments also increase treatment options, decrease problems, and streamline procedures, which support the market's growth.

Threat:

Risk of Complications

The risk of complications, such as pancreatitis, bleeding, or infections, prevents widespread use of ERCP devices. Particularly in high-risk situations, these possible hazards can discourage patients from choosing ERCP procedures and medical professionals from endorsing them. Additionally, as not all facilities may be prepared to carry out such sophisticated procedures safely; the requirement for highly qualified experts to reduce difficulties can raise costs and hinder market expansion.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Endoscopic Retrograde Cholangiopancreatography (ERCP) devices market, leading to delays and cancellations of elective procedures due to healthcare system strain. This resulted in reduced demand for ERCP devices. However, as healthcare systems recover, the market is expected to rebound with increased focus on minimally invasive diagnostic and therapeutic procedures, particularly for gastrointestinal and biliary disorders.

The biopsy forceps segment is expected to be the largest during the forecast period

The biopsy forceps segment is expected to be the largest during the forecast period because there is a growing need for precise diagnostic techniques for pancreatic and biliary disorders. During ERCP, biopsy forceps make it possible to take tissue samples, which aids in the early diagnosis of strictures, cancer, and other anomalies. The use of biopsy forceps is increased by the growing incidence of gastrointestinal disorders and improvements in minimally invasive procedures. Improved safety and accuracy are two more design elements that support market expansion.

The dilators segment is expected to have the highest CAGR during the forecast period

The dilators segment is expected to have the highest CAGR during the forecast period owing to the rising prevalence of biliary problems, advances in minimally invasive surgical techniques, and the increased desire for precise and effective procedures. In order to ensure smoother endoscope transit, dilators are necessary to dilate the strictures in the pancreatic and bile ducts. The market for ERCP devices is expanding as a result of technological advancements such disposable, ergonomic designs, and enhanced safety features that encourage the use of dilators.

Region with largest share:

North America is anticipated to hold the largest market share during the forecast period because biliary tract conditions like pancreatitis, cholangiocarcinoma, and gallstones are becoming more common. Treatment accuracy and patient outcomes are being improved by technological developments in ERCP devices, including as enhanced imaging systems and minimally invasive treatments. Furthermore, the region's high healthcare spending, well-established healthcare infrastructure, and rising use of cutting-edge medical technology all support the rising demand for ERCP devices, which in turn propels the market's expansion.

Region with highest CAGR:

Asia Pacific is anticipated to witness the highest CAGR over the forecast period due to increasing healthcare infrastructure, rising incidences of biliary and pancreatic diseases, and a growing aging population. Advancements in ERCP technologies, such as improved imaging and minimally invasive techniques, are enhancing diagnostic and therapeutic capabilities. Additionally, the region's expanding healthcare access, rising medical tourism and adoption of advanced medical devices are boosting the demand for ERCP devices, fueling market growth in Asia Pacific.

Key players in the market

Some of the key players in Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market include AMBU, Inc., B. Braun Melsungen AG, Boston Scientific Corporation, CONMED Corporation, Cook Group, FUJIFILM Holdings Corporation, Hobbs Medical, Inc., HOYA Group, Karl Storz SE & Co. KG, Medi-Globe GmbH, Medline Industries, Inc., Medtronic PLC, Olympus Corporation, Streis PLC, Stryker Corporation, Taewoong Medical Co., Ltd. and Telemed System, Inc.

Key Developments:

In September 2024, Medtronic expanded AiBLE spine surgery ecosystem with new technologies and Siemens Healthineers partnership.

In April 2024, Medtronic plc announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO(TM), the latest generation software for the GI Genius(TM) intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

In December 2023, Medtronic plc announced that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, to offer continued innovation and scalable healthcare advancements for patients and caregivers globally.

Products Covered:

  • Endotherapy Devices
  • Endoscopes
  • Imaging Devices
  • Sphincterotomes
  • Stents
  • Balloon Catheters
  • Biopsy Forceps
  • Guidewires
  • Dilators
  • Other Products

Types Covered:

  • Conventional ERCP
  • Single-Operator ERCP
  • Laparoscopic ERCP
  • Endoscopic Ultrasound (EUS)-Guided ERCP
  • Other Types

Technologies Covered:

  • Advanced Imaging Systems
  • Robotic-Assisted ERCP
  • Integration with AI and Machine Learning
  • Other Technologies

Applications Covered:

  • Diagnostic ERCP
  • Therapeutic ERCP
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Research and Academic Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Product

  • 5.1 Introduction
  • 5.2 Endotherapy Devices
  • 5.3 Endoscopes
  • 5.4 Imaging Devices
  • 5.5 Sphincterotomes
  • 5.6 Stents
  • 5.7 Balloon Catheters
  • 5.8 Biopsy Forceps
  • 5.9 Guidewires
  • 5.10 Dilators
  • 5.11 Other Products

6 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Type

  • 6.1 Introduction
  • 6.2 Conventional ERCP
  • 6.3 Single-Operator ERCP
  • 6.4 Laparoscopic ERCP
  • 6.5 Endoscopic Ultrasound (EUS)-Guided ERCP
  • 6.6 Other Types

7 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Technology

  • 7.1 Introduction
  • 7.2 Advanced Imaging Systems
  • 7.3 Robotic-Assisted ERCP
  • 7.4 Integration with AI and Machine Learning
  • 7.5 Other Technologies

8 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostic ERCP
    • 8.2.1 Cholangiocarcinoma
    • 8.2.2 Pancreatitis
    • 8.2.3 Gallstones
    • 8.2.4 Biliary Strictures
  • 8.3 Therapeutic ERCP
    • 8.3.1 Stone Extraction
    • 8.3.2 Stent Placement
    • 8.3.3 Sphincterotomy
    • 8.3.4 Dilation of Strictures
    • 8.3.5 Drainage of Infected Bile
  • 8.4 Other Applications

9 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Research and Academic Institutions
  • 9.6 Other End Users

10 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AMBU, Inc.
  • 12.2 B. Braun Melsungen AG
  • 12.3 Boston Scientific Corporation
  • 12.4 CONMED Corporation
  • 12.5 Cook Group
  • 12.6 FUJIFILM Holdings Corporation
  • 12.7 Hobbs Medical, Inc.
  • 12.8 HOYA Group
  • 12.9 Karl Storz SE & Co. KG
  • 12.10 Medi-Globe GmbH
  • 12.11 Medline Industries, Inc.
  • 12.12 Medtronic PLC
  • 12.13 Olympus Corporation
  • 12.14 Streis PLC
  • 12.15 Stryker Corporation
  • 12.16 Taewoong Medical Co., Ltd.
  • 12.17 Telemed System, Inc.